Believe it or not: how much can we rely on published data on potential drug targets?

被引：0

作者：

Florian Prinz

Thomas Schlange

Khusru Asadullah

机构：

[1] Florian Prinz is at Target Research Berlin,

[2] Bayer HealthCare,undefined

[3] Müllerstraße 178,undefined

[4] 13342 Berlin,undefined

[5] Germany.,undefined

[6] Thomas Schlange is at Target Research Wuppertal,undefined

[7] Bayer HealthCare,undefined

[8] Aprather Weg 18a,undefined

[9] 42096 Wuppertal,undefined

[10] Germany.,undefined

[11] Khusru Asadullah is Vice President and Head of Target Discovery at Bayer HealthCare,undefined

[12] Müllerstraße 178,undefined

[13] 13342 Berlin,undefined

[14] Germany.,undefined

来源：

Nature Reviews Drug Discovery | 2011年 / 10卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：712 / 712

共 12 条

[1]

Arrowsmith J(2011)Phase II failures: 2008–2010 Nature Rev. Drug Discov. 10 328-329

[2]

Osherovich Lev(2011)Hedging against academic risk Science-Business eXchange 4 416-416

[3]

Barrows NJ(2010)Factors affecting reproducibility between genome-scale siRNA-based screens J. Biomol. Screen. 15 735-747

[4]

Le Sommer C(2005)Why most published research findings are false PLoS Med. 2 e124-514

[5]

Garcia-Blanco MA(2008)What errors do peer reviewers detect, and does training improve their ability to detect them? J. R. Soc. Med. 101 507-607

[6]

Pearson JL(2001)What happens to the manuscripts that have not been accepted for publication in Occup. Environ. Med. 58 604-1434

[7]

Ioannidis JP(2007)? Am. J. Neuroradiol. 28 1430-undefined

[8]

Schroter S(undefined)Fate of submitted manuscripts rejected from the American Journal of Neuroradiology: outcomes and commentary undefined undefined undefined-undefined

[9]

Nemery B(undefined)undefined undefined undefined undefined-undefined

[10]

McDonald RJ(undefined)undefined undefined undefined undefined-undefined

← 1 2 →